Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
Portfolio Pulse from
Ademi LLP is investigating Intra-Cellular Therapies for potential breaches of fiduciary duty in its transaction with Johnson & Johnson, where shareholders will receive $132 per share.
January 13, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ademi LLP is investigating Intra-Cellular Therapies for potential breaches of fiduciary duty in its transaction with Johnson & Johnson, where shareholders will receive $132 per share.
The investigation by Ademi LLP into potential breaches of fiduciary duty could lead to legal challenges or delays in the transaction, potentially affecting ITCI's stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100